메뉴 건너뛰기




Volumn 70, Issue 5, 2012, Pages 743-754

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma

Author keywords

BRCA1; Class III b Tubulin; ERCC1; Malignant mesothelioma; Predictive biomarker

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; BRCA1 PROTEIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NAVELBINE; UNCLASSIFIED DRUG;

EID: 84871250353     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1965-0     Document Type: Article
Times cited : (17)

References (44)
  • 2
    • 46349091630 scopus 로고    scopus 로고
    • Current concepts in chemotherapy for malignant pleural mesothelioma
    • Sorensen JB (2008) Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J 2:74-79
    • (2008) Clin Respir J , vol.2 , pp. 74-79
    • Sorensen, J.B.1
  • 4
    • 79851511500 scopus 로고    scopus 로고
    • Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    • Gridelli C, De MF, Di MM et al (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer 71:249-257
    • (2011) Lung Cancer , vol.71 , pp. 249-257
    • Gridelli, C.1    De, M.F.2    Di, M.M.3
  • 5
    • 0024337144 scopus 로고
    • Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3
  • 6
    • 20044364933 scopus 로고    scopus 로고
    • Egfr mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
    • Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865
    • (2005) J Clin Oncol , vol.23 , pp. 857-865
    • Marchetti, A.1    Martella, C.2    Felicioni, L.3
  • 7
    • 0345256652 scopus 로고    scopus 로고
    • Cisplatin: Mode of cytotoxic action and molecular basis of resistance
    • Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
    • (2003) Oncogene , vol.22 , pp. 7265-7279
    • Siddik, Z.H.1
  • 8
    • 40949130371 scopus 로고    scopus 로고
    • Platinum resistance: The role of dna repair pathways
    • Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291-1295
    • (2008) Clin Cancer Res , vol.14 , pp. 1291-1295
    • Martin, L.P.1    Hamilton, T.C.2    Schilder, R.J.3
  • 9
    • 77956124352 scopus 로고    scopus 로고
    • Ercc1 and histopathology in advanced nsclc patients randomized in a large multicenter phase iii trial
    • Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21:1817-1824
    • (2010) Ann Oncol , vol.21 , pp. 1817-1824
    • Vilmar, A.C.1    Santoni-Rugiu, E.2    Sorensen, J.B.3
  • 10
    • 33748435058 scopus 로고    scopus 로고
    • Dna repair by ercc1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    • Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991
    • (2006) N Engl J Med , vol.355 , pp. 983-991
    • Olaussen, K.A.1    Dunant, A.2    Fouret, P.3
  • 11
    • 69449090272 scopus 로고    scopus 로고
    • The relationship of platinum resistance and ercc1 protein expression in epithelial ovarian cancer
    • Steffensen KD, Waldstrom M, Jakobsen A (2009) The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19:820-825
    • (2009) Int J Gynecol Cancer , vol.19 , pp. 820-825
    • Steffensen, K.D.1    Waldstrom, M.2    Jakobsen, A.3
  • 12
    • 78649497050 scopus 로고    scopus 로고
    • Excision repair crosscomplementation group 1 (ercc1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
    • Kim KH, Do IG, Kim HS et al (2010) Excision repair crosscomplementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 118:941-948
    • (2010) APMIS , vol.118 , pp. 941-948
    • Kim, K.H.1    Do, I.G.2    Kim, H.S.3
  • 13
    • 9744263911 scopus 로고    scopus 로고
    • The role of brca1 in the cellular response to chemotherapy
    • Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668
    • (2004) J Natl Cancer Inst , vol.96 , pp. 1659-1668
    • Kennedy, R.D.1    Quinn, J.E.2    Mullan, P.B.3
  • 14
    • 0037403380 scopus 로고    scopus 로고
    • Improved survival in women with brca-Associated ovarian carcinoma
    • Cass I, Baldwin RL, Varkey T et al (2003) Improved survival in women with BRCA-Associated ovarian carcinoma. Cancer 97:2187-2195
    • (2003) Cancer , vol.97 , pp. 2187-2195
    • Cass, I.1    Baldwin, R.L.2    Varkey, T.3
  • 15
    • 19544379515 scopus 로고    scopus 로고
    • Brca1 mrna expression levels as an indicator of chemoresistance in lung cancer
    • Taron M, Rosell R, Felip E et al (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449
    • (2004) Hum Mol Genet , vol.13 , pp. 2443-2449
    • Taron, M.1    Rosell, R.2    Felip, E.3
  • 16
    • 21444446876 scopus 로고    scopus 로고
    • Differential sensitivity of brca1-mutated hcc1937 human breast cancer cells to microtubule-interfering agents
    • Tassone P, Blotta S, Palmieri C et al (2005) Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 26:1257-1263
    • (2005) Int J Oncol , vol.26 , pp. 1257-1263
    • Tassone, P.1    Blotta, S.2    Palmieri, C.3
  • 17
    • 65649146783 scopus 로고    scopus 로고
    • A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of brca1
    • Stordal B, Davey R (2009) A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 9:354-365
    • (2009) Curr Cancer Drug Targets , vol.9 , pp. 354-365
    • Stordal, B.1    Davey, R.2
  • 18
    • 0141954010 scopus 로고    scopus 로고
    • Brca1 functions as a differential modulator of chemotherapy-induced apoptosis
    • Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221-6228
    • (2003) Cancer Res , vol.63 , pp. 6221-6228
    • Quinn, J.E.1    Kennedy, R.D.2    Mullan, P.B.3
  • 19
    • 33847304077 scopus 로고    scopus 로고
    • Brca1-A good predictive marker of drug sensitivity in breast cancer treatment
    • Mullan PB, Gorski JJ, Harkin DP (2006) BRCA1-A good predictive marker of drug sensitivity in breast cancer treatment Biochim Biophys Acta 1766:205-216
    • (2006) Biochim Biophys Acta , vol.1766 , pp. 205-216
    • Mullan, P.B.1    Gorski, J.J.2    Harkin, D.P.3
  • 20
    • 77649191871 scopus 로고    scopus 로고
    • Microtubules and resistance to tubulinbinding agents
    • Kavallaris M (2010) Microtubules and resistance to tubulinbinding agents. Nat Rev Cancer 10:194-204
    • (2010) Nat Rev Cancer , vol.10 , pp. 194-204
    • Kavallaris, M.1
  • 21
    • 35148854099 scopus 로고    scopus 로고
    • Class iii beta-Tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer
    • Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-Tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67:9356-9363
    • (2007) Cancer Res , vol.67 , pp. 9356-9363
    • Gan, P.P.1    Pasquier, E.2    Kavallaris, M.3
  • 22
    • 38549161093 scopus 로고    scopus 로고
    • Is class iii beta-Tubulin a predictive factor in patients receiving tubulin-binding agents
    • Seve P, Dumontet C (2008) Is class III beta-Tubulin a predictive factor in patients receiving tubulin-binding agents Lancet Oncol 9:168-175
    • (2008) Lancet Oncol , vol.9 , pp. 168-175
    • Seve, P.1    Dumontet, C.2
  • 23
    • 23044435044 scopus 로고    scopus 로고
    • Expression of class iii {beta}-Tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
    • Seve P, Isaac S, Tredan O et al (2005) Expression of class III {beta}-Tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-5486
    • (2005) Clin Cancer Res , vol.11 , pp. 5481-5486
    • Seve, P.1    Isaac, S.2    Tredan, O.3
  • 24
    • 30344437279 scopus 로고    scopus 로고
    • Class iii beta-Tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
    • Seve P, Mackey J, Isaac S et al (2005) Class III beta-Tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007
    • (2005) Mol Cancer Ther , vol.4 , pp. 2001-2007
    • Seve, P.1    Mackey, J.2    Isaac, S.3
  • 25
    • 79961005073 scopus 로고    scopus 로고
    • Class iii {beta}-Tubulin in advanced nsclc of adenocarcinoma subtype predicts superior outcome in a randomized trial
    • Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III {beta}-Tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17:5205-5214
    • (2011) Clin Cancer Res , vol.17 , pp. 5205-5214
    • Vilmar, A.C.1    Santoni-Rugiu, E.2    Sorensen, J.B.3
  • 26
    • 34147187180 scopus 로고    scopus 로고
    • Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-Tubulins
    • Tommasi S, Mangia A, Lacalamita R et al (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-Tubulins. Int J Cancer 120:2078-2085
    • (2007) Int J Cancer , vol.120 , pp. 2078-2085
    • Tommasi, S.1    Mangia, A.2    Lacalamita, R.3
  • 27
    • 34247403761 scopus 로고    scopus 로고
    • Class iii beta-Tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
    • Seve P, Reiman T, Lai R et al (2007) Class III beta-Tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27-34
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 27-34
    • Seve, P.1    Reiman, T.2    Lai, R.3
  • 28
    • 84655170221 scopus 로고    scopus 로고
    • Low ercc1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival
    • Zimling ZG, Sorensen JB, Gerds TA et al (2012) Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 7:249-256
    • (2012) J Thorac Oncol , vol.7 , pp. 249-256
    • Zimling, Z.G.1    Sorensen, J.B.2    Gerds, T.A.3
  • 29
    • 46349111832 scopus 로고    scopus 로고
    • Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
    • Sorensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99:44-50
    • (2008) Br J Cancer , vol.99 , pp. 44-50
    • Sorensen, J.B.1    Frank, H.2    Palshof, T.3
  • 30
    • 0029670327 scopus 로고    scopus 로고
    • A proposed new international tnm staging system for malignant pleural mesothelioma from the international mesothelioma interest group
    • Rusch VW (1996) A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1-12
    • (1996) Lung Cancer , vol.14 , pp. 1-12
    • Rusch, V.W.1
  • 31
    • 1342267614 scopus 로고    scopus 로고
    • Modified recist criteria for assessment of response in malignant pleural mesothelioma
    • Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260
    • (2004) Ann Oncol , vol.15 , pp. 257-260
    • Byrne, M.J.1    Nowak, A.K.2
  • 32
    • 33746004548 scopus 로고    scopus 로고
    • Progression-free survival rate as primary end point for phase ii cancer clinical trials: Application to mesothelioma -The eortc lung cancer group
    • Francart J, Legrand C, Sylvester R et al (2006) Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma -The EORTC Lung Cancer Group. J Clin Oncol 24:3007-3012
    • (2006) J Clin Oncol , vol.24 , pp. 3007-3012
    • Francart, J.1    Legrand, C.2    Sylvester, R.3
  • 33
    • 0028113345 scopus 로고
    • A strong candidate for the breast and ovarian cancer susceptibility gene brca1
    • Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
    • (1994) Science , vol.266 , pp. 66-71
    • Miki, Y.1    Swensen, J.2    Shattuck-Eidens, D.3
  • 34
    • 0029115660 scopus 로고
    • The developmental pattern of brca1 expression implies a role in differentiation of the breast and other tissues
    • Marquis ST, Rajan JV, Wynshaw-Boris A et al (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11:17-26
    • (1995) Nat Genet , vol.11 , pp. 17-26
    • Marquis, S.T.1    Rajan, J.V.2    Wynshaw-Boris, A.3
  • 35
    • 0033055801 scopus 로고    scopus 로고
    • Reduction of brca1 protein expression in japanese sporadic breast carcinomas and its frequent loss in brca1-Associated cases
    • Yoshikawa K, Honda K, Inamoto T et al (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-Associated cases. Clin Cancer Res 5:1249-1261
    • (1999) Clin Cancer Res , vol.5 , pp. 1249-1261
    • Yoshikawa, K.1    Honda, K.2    Inamoto, T.3
  • 36
    • 51049119252 scopus 로고    scopus 로고
    • Proteomic characterization of cytoskeletal and mitochondrial class iii beta-Tubulin
    • Cicchillitti L, Penci R, Di MM et al (2008) Proteomic characterization of cytoskeletal and mitochondrial class III beta-Tubulin. Mol Cancer Ther 7:2070-2079
    • (2008) Mol Cancer Ther , vol.7 , pp. 2070-2079
    • Cicchillitti, L.1    Penci R Di, M.M.2
  • 37
    • 77954321859 scopus 로고    scopus 로고
    • Metastatic non-smallcell lung cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up
    • D'Addario G, Fruh M, Reck M et al (2010) Metastatic non-smallcell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116-v119
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • D'Addario, G.1    Fruh, M.2    Reck, M.3
  • 38
    • 34248378221 scopus 로고    scopus 로고
    • Expression of betatubulin isotypes in human primary ovarian carcinoma
    • Ohishi Y, Oda Y, Basaki Y et al (2007) Expression of betatubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 105:586-592
    • (2007) Gynecol Oncol , vol.105 , pp. 586-592
    • Ohishi, Y.1    Oda, Y.2    Basaki, Y.3
  • 39
    • 84255206496 scopus 로고    scopus 로고
    • Cross-validation study of class iii beta-Tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials
    • Reiman T, Lai R, Veillard AS et al (2012) Cross-validation study of class III beta-Tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23:86-93
    • (2012) Ann Oncol , vol.23 , pp. 86-93
    • Reiman, T.1    Lai, R.2    Veillard, A.S.3
  • 40
    • 71049134390 scopus 로고    scopus 로고
    • Expression of ercc1 and class iiibeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer
    • Ikeda S, Takabe K, Suzuki K (2009) Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 59:863-867
    • (2009) Pathol Int , vol.59 , pp. 863-867
    • Ikeda, S.1    Takabe, K.2    Suzuki, K.3
  • 41
    • 67349275022 scopus 로고    scopus 로고
    • Expression of ercc1 and class iii beta-Tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
    • Azuma K, Sasada T, Kawahara A et al (2009) Expression of ERCC1 and class III beta-Tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326-333
    • (2009) Lung Cancer , vol.64 , pp. 326-333
    • Azuma, K.1    Sasada, T.2    Kawahara, A.3
  • 42
    • 0034548837 scopus 로고    scopus 로고
    • Phase ii study of vinorelbine in patients with malignant pleural mesothelioma
    • Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917
    • (2000) J Clin Oncol , vol.18 , pp. 3912-3917
    • Steele, J.P.1    Shamash, J.2    Evans, M.T.3
  • 43
    • 0036852721 scopus 로고    scopus 로고
    • Automated subcellular localization and quantification of protein expression in tissue microarrays
    • Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327
    • (2002) Nat Med , vol.8 , pp. 1323-1327
    • Camp, R.L.1    Chung, G.G.2    Rimm, D.L.3
  • 44
    • 69749092500 scopus 로고    scopus 로고
    • Standardization of her2 immunohistochemistry in breast cancer by automated quantitative analysis
    • Gustavson MD, Bourke-Martin B, Reilly D et al (2009) Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 133:1413-1419
    • (2009) Arch Pathol Lab Med , vol.133 , pp. 1413-1419
    • Gustavson, M.D.1    Bourke-Martin, B.2    Reilly, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.